Download
s00066-021-01823-z.pdf 169,71KB
WeightNameValue
1000 Titel
  • Moderate Dosisdeeskalation der definitiven Cisplatin-basierten Radiochemotherapie für HPV-positive Oropharynxkarzinompatienten
1000 Titelzusatz
  • Moderate dose de-escalation of cisplatin-based chemoradiation for HPV-associated oropharyngeal carcinoma
1000 Autor/in
  1. Rühle, Alexander |
  2. Nicolay, Nils H. |
1000 Erscheinungsjahr 2021
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2021-07-26
1000 Erschienen in
1000 Quellenangabe
  • 197(10):950-952
1000 Copyrightjahr
  • 2021
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00066-021-01823-z |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8458172/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose!#!The aim of this study was to evaluate the safety and long-term tumor control after stereotactic radiotherapy (SRT) with 12 × 6 Gy of patients with primary bronchial carcinoma (BC) or with pulmonary metastases (MET) of various solid tumors. Local progression-free survival (LPFS), progression-free survival (PFS), overall survival (OS), and prognostic factors were compared.!##!Methods!#!Between May 2012 and January 2020, 168 patients with 206 pulmonary lesions (170 MET and 36 primary BC) were treated with 12 × 6 Gy (BED!##!Results!#!The median follow-up was 16.26 months (range: 0.46-89.34) for BC and 19.18 months (0.89-91.11) for MET. Survival rates at 3 years were: OS 43% for BC and 35% for MET; LPFS BC 96% and MET 85%; PFS BC 35% and MET 29%. The most frequently observed grade 3 adverse events (AEs) were pneumonitis (5.9% BC, 4.8% MET), pulmonary fibrosis (2.9% BC, 4% MET), and pulmonary embolism (2.9% BC, 0.8% MET). The favorable prognostic effects on overall survival of patients with MET were female gender (log-rank: p < 0.001), no systemic progression (log-rank; p = 0.048, multivariate COX regression p = 0.039), and malignant melanoma histology (log-rank; p = 0.015, multivariate COX regression p = 0.020). For patients with BC, it was tumor location within the lower lobe (vs. upper lobe, log-rank p = 0.027). LPFS of patients with metastatic disease was beneficially influenced by female gender (log-rank: p = 0.049).!##!Conclusion!#!The treatment concept of 12 × 6 Gy is associated with 96% local progression-free survival for BC and 85% for pulmonary metastases after 3 years. There was no difference in response after SRT of primary lung carcinoma or pulmonary metastases.
1000 Sacherschließung
lokal Oropharyngeal Neoplasms/pathology [MeSH]
lokal Carcinoma [MeSH]
lokal Humans [MeSH]
lokal Chemoradiotherapy/methods [MeSH]
lokal Papillomavirus Infections [MeSH]
lokal Literatur Kommentiert
lokal Cisplatin [MeSH]
lokal Oncology
lokal Radiotherapy
lokal Oropharyngeal Neoplasms/therapy [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UsO8aGxlLCBBbGV4YW5kZXI=|https://frl.publisso.de/adhoc/uri/Tmljb2xheSwgTmlscyBILg==
1000 Hinweis
  • DeepGreen-ID: b5520ae5e8424ae180109cd98c5a620c ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6448593.rdf
1000 Erstellt am 2023-05-03T18:55:00.187+0200
1000 Erstellt von 322
1000 beschreibt frl:6448593
1000 Zuletzt bearbeitet Fri Oct 13 16:57:07 CEST 2023
1000 Objekt bearb. Fri Oct 13 16:57:07 CEST 2023
1000 Vgl. frl:6448593
1000 Oai Id
  1. oai:frl.publisso.de:frl:6448593 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source